FDA Brief

Warning letters Drugs

FDA warning letter to

Thai Nakorn Patana Co., Ltd.

High riskIssued Feb 27, 2024Posted Mar 5, 2024Center for Drug Evaluation and Research | CDER

FDA warns Thai Nakorn Patana over manufacturing quality violations, including missing identity and strength testing before release of OTC drugs.

What happened

FDA inspected the drug manufacturing facility in Nonthaburi, Thailand, from July 31 to August 4, 2023. FDA found the company released OTC drug products without adequate testing for identity and strength of active ingredients, and found quality-unit oversight failures in process validation, test methods, data retention, investigations, and cleaning. The company committed to stop making Neotica Crème drugs for the U.S. market.

What FDA found

  1. The company released drug batches without testing each batch for identity and strength of active ingredients against final specifications.

    21 CFR 211.165(a)
  2. The quality control unit did not adequately oversee manufacturing to ensure compliance with manufacturing quality rules and product specifications.

    21 CFR 211.22
  3. The company lacked adequate production and process controls, including process validation, to assure identity, strength, quality, and purity.

    21 CFR 211.100(a)
  4. The company did not use scientifically sound and appropriate test methods and standards for its drug products.

    21 CFR 211.160(b)
  5. The company did not properly document and retain complete data from standard preparation, sample preparation, and assay testing.

    21 CFR 211.194(a)
  6. The company did not conduct adequate investigations and deviations, and lacked adequate cleaning and maintenance procedures, including cleaning validation for non-dedicated equipment.

    21 CFR 211.192; 21 CFR 211.67(a)

What FDA wants

Respond in writing within 15 working days with corrective actions and steps to prevent recurrence; if actions cannot be completed, give reasons and a schedule. FDA also asks the company to clarify whether it will resume U.S. drug manufacturing, notify FDA before resuming, and recommends a qualified consultant and full audit.

Who should pay attention

  • U.S. distributors and retailers of imported OTC drugs
  • companies using Thai Nakorn Patana as a contract manufacturer
  • quality teams that qualify foreign drug suppliers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk